Piramal, Cumberland Pharma set out to co-promote two products in USA

Piramal Critical Care, a unit of India’s Piramal Enterprises (BSE: 500302), and Cumberland Pharmaceuticals (Nasdaq: CPIX) on Tuesday said they have launched the co-promotion of two of Cumberland's products, Caldolor (ibuprofen) and Vaprisol (conivaptan hydrochloride) in the US.

AJ Kazimi, chief executive of Cumberland Pharmaceuticals, said: "We welcome Piramal as a co-promotion partner in the US and believe this new collaboration will enhance Cumberland's ability to further advance patient care through the delivery of high quality pharmaceutical products in this country."

Caldolor (ibuprofen) Injection is the first injectable product approved in this country for the treatment of pain and fever in adults. The brand recently received US Food and Drug Administration approval to manage pain and reduce fever for pediatric patients. Vaprisol is the only injectable brand available to treat hyponatremia, the most common electrolyte imbalance in US hospitalized patients.